This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a before-and-after study that was carried out in a single centre. The duration of follow-up was one year for each management practice. Four patients from group A died before the start of the programme.
Analysis of effectiveness
Not all of the patients included in the study were accounted for in the analysis. The primary health outcomes used in the effectiveness analysis were the New York Heart Association (NYHA) functional class for patients in groups A and B (where a higher class number meant that the patient presented more limitations in their physical activity due to left ventricular failure) and the total number of admissions. These were assessed before and after the implementation of the heart failure MDMP. The percentages of patients receiving angiotensin-converting enzyme inhibitors (ACE-I) and betablockers before and after programme implementation were also reported. The baseline demographic characteristics of the groups (e.g. age, gender, ethnicity and education) were also reported. The comparability of the groups was not an issue since this was a before-and-after study for two groups.
Effectiveness results
The authors reported baseline values and 1-year outcomes for both groups, A and B. At baseline, 10 patients in group A were NYHA functional class III and 4 were NYHA functional class IV. However, the baseline figures quoted in another table were different. After programme implementation, 12 patients were NYHA functional class II and 2 were NYHA functional class III. The differences between both periods were statistically significant, (p<0.001). The number of admissions within this group decreased from 33 before the implementation of the programme to 3 after its implementation.
In group B, before the implementation of the programme, 10 patients were NYHA functional class II and 11 were NYHA functional class III. Again, different figures were reported elsewhere. After programme implementation, 10 patients were NYHA functional class I and 11 were NYHA functional class II. The differences between both periods were statistically significant, (p<0.001). The number of admissions decreased significantly from 9 in the year prior to the implementation of the programme to zero after the programme was implemented, (p=0.002).
Before the implementation of the programme, 36% of patients in group A and 76% in group B were receiving ACE-I. In addition, 7% of the patients in group A and 38% in group B were receiving beta-blockers. After the programme was implemented, these values were 71% (group A) and 76% (group B) for the administration of ACE-I, and 14% (group A) and 48% (group B) for the administration of beta-blockers.
Clinical conclusions
The health state of the patients improved, as shown by the significant improvements in the NYHA functional class and the reduced number of hospitalisations after the implementation of the heart failure MDMP.
Measure of benefits used in the economic analysis
There was no summary measure of health benefit in the economic analysis. The study was therefore categorised as a cost-consequences study.
Validity of estimate of measure of effectiveness
The analysis used a before-and-after study for two patient groups, which may have been appropriate for the institution that undertook the study. However, there are problems with this type of design. There may not have been any selection bias, but there may have been performance bias since the patients' improvement may have been partially due to the healing power of time rather than the programme itself. The authors did not provide evidence that the study sample was representative of the study population. Further, the four deaths in group A may have biased the results if their rate of admissions was higher than average. Statistical analyses were not performed to take account of potential biases, but only to show that there were statistically significant differences in the primary health outcomes between the periods before and after MDMP implementation. The authors reported that a limitation of the study was the very small sample size. Since the comparator was not explicitly described, it is hard to say to what the study results were attributable. There seems to have been inconsistencies in the reporting of the results.
Validity of estimate of measure of benefit
The authors did not derive a summary measure of health benefit. The study was therefore categorised as a costconsequences analysis.
Validity of estimate of costs
The reporting of the costs was very brief, the study perspective was not stated clearly and some important information was not reported, such as the different cost categories included in the economic analysis. Therefore, it cannot be stated with certainty that all of the relevant costs were included. Some relevant costs appear not to have been included in the economic analysis, such as the costs of implementing the heart failure MDMP (e.g. staff-related costs and medication). These costs should have been considered in the economic analysis so that appropriate comparisons of the situation before and after the implementation of the intervention could be made. Charges were used instead of costs, which may not reflect the opportunity costs of the intervention. The resource quantities and the costs were not reported separately, and the price year was not stated. All these factors introduce uncertainty into the reliability of the conclusions and hinder reflation exercises to other settings.
